CIK 0001549595 · Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 270838048
- Phone
- (415) 660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,886 | 33,888 | ||
| 2024-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +2,000 | 35,888 | ||
| 2024-10-30 | van Houte Hans Chief Financial Officer | Option exercise | +3,750 | 39,638 | ||
| 2024-10-30 | van Houte Hans Chief Financial Officer | Sale | −2,368 | $24.31 | $58K | 37,270 |
| 2024-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,886 | 14,431 | ||
| 2024-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −2,000 | 12,000 | ||
| 2024-10-30 | van Houte Hans Chief Financial Officer | Option exercise · Restricted Stock Units | −3,750 | 37,500 | ||
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,207 | 48,357 | ||
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +2,000 | 50,357 | ||
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise | +3,750 | 54,107 | ||
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Sale | −3,437 | $24.31 | $84K | 50,670 |
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,207 | 16,034 | ||
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −2,000 | 12,000 | ||
| 2024-10-30 | Hansen Gwenn Chief Scientific Officer | Option exercise · Restricted Stock Units | −3,750 | 37,500 | ||
| 2024-10-30 | Ring Christine Chief Legal Officer | Option exercise | +1,924 | 26,516 | ||
| 2024-10-30 | Ring Christine Chief Legal Officer | Option exercise | +2,000 | 28,516 | ||
| 2024-10-30 | Ring Christine Chief Legal Officer | Option exercise | +3,750 | 32,266 | ||
| 2024-10-30 | Ring Christine Chief Legal Officer | Sale | −4,182 | $24.31 | $102K | 28,084 |
| 2024-10-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −1,924 | 9,621 | ||
| 2024-10-30 | Ring Christine Chief Legal Officer | Option exercise · Restricted Stock Units | −2,000 | 12,000 |
Page 17 of 20 · 381 trades